Sun et al. (97) demonstrate that pharmacological inhibition of the PI3K/AKT/mTOR signaling pathway induces autophagic activation, which subsequently attenuates intracellular lipid accumulation, suppresses inflammatory responses, and ameliorates MASLD. Here, AKT1 is linked to metabolic dysfunction-associated steatotic liver disease.